Birchview Capital’s Gilead Sciences GILD Stock Holding History

Birchview Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,000	Closed	-$769K	–	51
2020 Q2	$769K	Sell	10,000 -10,000	-50%	-$766K	0.46%	30
2020 Q1	$1.5M	Buy	+20,000	New	+$1.38M	1.33%	13
2016 Q1	–	Sell	-3,820	Closed	-$387K	–	42
2015 Q4	$387K	Sell	3,820 -9,000	-70%	-$936K	0.22%	26
2015 Q3	$1.26M	Sell	12,820 -5,850	-31%	-$650K	0.81%	11
2015 Q2	$2.19M	Hold	18,670	–	–	1.15%	9
2015 Q1	$1.83M	Hold	18,670	–	–	0.96%	10
2014 Q4	$1.76M	Buy	+18,670	New	+$1.93M	1.02%	9

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Birchview Capital's GILD Position: Q3 2020 in Review

Birchview Capital sold out of Gilead Sciences (GILD) in Q3 2020, closing a stake of 10,000 shares — an estimated $769K sold.

Birchview Capital first reported a position in GILD in Q4 2014 and held it in 7 quarters. The position peaked at $2.19M in Q2 2015. 1,538 funds tracked by Wall St. Rank hold GILD as of Q3 2020.

Birchview Capital reported no remaining Gilead Sciences position as of Q3 2020 after selling out during the quarter.
Birchview Capital sold 10,000 Gilead Sciences shares in Q3 2020, an estimated $769K.
Birchview Capital first reported a position in Gilead Sciences in Q4 2014 and held it in 7 quarters.
Birchview Capital's Gilead Sciences position peaked at $2.19M in Q2 2015.
1,538 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2020.

Based on Birchview Capital's 13F filing for Q3 2020, filed 12 Nov 2020.